Novartis AG is deepening its commitment to kidney disease by teaming up with Versant Ventures to create Borealis Biosciences, which will use its $150m series A funding round from the two to develop RNA-based drugs in renal diseases.
Borealis Seeks Aurora In RNA-Based Drugs For Renal Disease
With $150m in series A funding, the Versant- and Novartis-backed start-up is betting it can overcome the challenges to getting RNA medicines into the kidney.
More from Financing
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.